

Filed on behalf of Petitioner FLATWING PHARMACEUTICALS, LLC

By: Philip D. Segrest, Jr.  
HUSCH BLACKWELL LLP  
120 South Riverside Plaza, Suite 2200  
Chicago, Illinois 60606  
Philip.Segrest@HuschBlackwell.com  
Tel. (312) 655-1500  
Fax. (312) 655-1501

---

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

FlatWing Pharmaceuticals, LLC,

*Petitioner,*

v.

Anacor Pharmaceuticals, Inc.,

*Patent Owner.*

Case No.: 2018-00169

Patent No. 9,566,289

---

**DECLARATION OF STEPHEN KAHL PH.D. IN SUPPORT OF PETITION  
FOR INTER PARTES REVIEW OF PATENT NO. 9,566,289**

---

**TABLE OF CONTENTS**

**TABLE OF CONTENTS ..... I**

**DECLARATION.....1**

I. INTRODUCTION .....1

II. BACKGROUND AND EXPERIENCE .....1

III. COMPENSATION AND RELATIONSHIP TO THE PARTIES .....3

IV. MATERIALS CONSIDERED .....4

V. LEGAL STANDARDS .....7

VI. LEVEL OF ORDINARY SKILL IN THE ART .....8

VII. THE '289 PATENT AND RELEVANT PROSECUTION HISTORY .....10

VIII.OPINIONS .....12

IX. CONCLUSION .....18

## **DECLARATION**

I, Stephen Kahl, Ph.D., hereby state the following:

### **I. INTRODUCTION**

1. In this declaration, I am providing my expert opinions in support of the above-captioned petition for *inter partes* review (“IPR”) of U.S. Patent No. 9,566,289 (“the ’289 Patent”) filed by petitioner (FlatWing Pharmaceuticals, LLC), which challenges the patentability of claims 1–15 of the ’289 Patent.

2. This Declaration sets forth the bases and reasons for my opinions.

3. This Declaration is based on information currently available to me. I reserve the right to continue my investigation and analysis, which may include a review of documents and information not yet produced. I further reserve the right to expand or otherwise modify my opinions and conclusions as my investigation and study continues, and to supplement my opinions and conclusions in response to any additional information that becomes available to me.

### **II. BACKGROUND AND EXPERIENCE**

4. I received a B.S. in Chemistry from Duke University (1964-68) and a Ph.D. in Chemistry from Indiana University (1968-72).

5. From 1972 until 1974, I was a Postdoctoral Fellow at the University of California, Berkeley in the Departments of Chemistry and Physics. From 1975 until 1982, I was an Assistant Professor at Wellesley College in the Department of

Chemistry. From 1982 until the present, I have held the following positions in the Department of Pharmaceutical Chemistry at the University of California, San Francisco: Visiting Assistant Professor (1982–1985); Assistant Professor In Residence (1985–1990); Associate Professor In Residence (1990–1995); Professor in Residence (1995–2011); and Professor In Residence Emeritus (2011–Present). I also served as Vice Chair of the UCSF Department of Pharmaceutical Chemistry from 1993 to 2013. From 1983 to 2015, I held the title of Visiting Professor (Lecturer) in the Department of Chemistry at Stanford University.

6. I have received numerous honors and awards, including the Dean’s Recognition for Excellence in Teaching, University of California School of Pharmacy on nine different occasions since its inception in 2005.

7. I have also served as an *Ad Hoc* Reviewer for twenty journals including: JOURNAL OF MEDICINAL CHEMISTRY (1985–Present); JOURNAL OF ORGANIC CHEMISTRY (1991–Present); CANCER RESEARCH (1989–Present); PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, USA (1990–Present); and JOURNAL OF AMERICAN CHEMICAL SOCIETY (1986–Present).

8. My research interests over my career have related to the development of organic synthetic methodologies and separation techniques for the preparation of bioactive boron molecules specifically targeted to biological systems, e.g. cancer cells, atherosclerotic plaques, and viral and parasitic vectors, and the application of

methods to assess the toxicology and gross and subcellular biodistribution of these molecules. To date, my research has resulted in over 65 publications in books and peer reviewed journals; and over 30 invited presentations.

9. My CV, which lists in further detail my relevant professional experience, is attached as Exhibit 1004.

10. I am informed that in proceedings on patents in the same patent family claiming priority to the same disclosure, the Board determined that I was “qualified to testify as to the knowledge of a person of ordinary skill in the art in this proceeding.” *Coalition for Affordable Drugs X LLC v. Anacor Pharmaceuticals, Inc.*, IPR2015-01780, Paper 70 at 11 (P.T.A.B. Feb. 23, 2017).

### **III. COMPENSATION AND RELATIONSHIP TO THE PARTIES**

11. I am being compensated at my standard consulting rate of \$500 per hour for the time I spend studying materials and issues associated with this matter and \$750 per hour for the time I spend providing testimony. My compensation is not contingent upon the outcome of this matter. I expect to be reimbursed for reasonable expenses associated with travel, including lodging, transportation, and other expenses incurred in connection with this matter.

12. It is my understanding that Anacor Pharmaceuticals Inc. (“Anacor”) is the assignee of the ’289 Patent. Prior to this matter, I have not worked for Anacor or had any vested interest in the Petitioner or its related entities. I own no stock or

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.